Kevin C. Eggan
Kevin C. Eggan, Ph.D.
Kevin Eggan is an institute member at the Broad Institute and the director of stem cell biology at the Broad’s Stanley Center for Psychiatric Research. He is also a professor in the Department of Stem Cell and Regenerative Biology at Harvard University and a principal investigator at the Harvard Stem Cell Institute.
Eggan has garnered international recognition and a number of high-profile awards, including the MacArthur Foundation “Genius Grant” in 2006. His research focuses on applying the knowledge gained in stem cell biology to study the mechanisms underlying amyotrophic lateral sclerosis (ALS) and discover new therapeutic targets. Eggan published high-impact papers in Cell Stem Cell and Science in 2008. One described the discovery that motor neurons derived from human embryonic stem cells are susceptible to the toxic effect of glial cells harboring an ALS mutation. The other showed that induced pluripotent stem (iPS) cells generated from adult skin cells of ALS patients can be differentiated into motor neurons. From 2009 to 2015, Eggan was an early career scientist of the Howard Hughes Medical Institute (HHMI). He used HHMI’s support to study the pathobiology of ALS using stem cell derived disease models. Currently, Eggan and colleagues are extending their expertise beyond motor neuron disease to include psychiatric conditions and using 3D organoid cultures to study maladies arising from faulty neuronal development.
Eggan received his B.S. in microbiology from the University of Illinois and his Ph.D. in biology from MIT, where he focused on cloning, stem cells, and reprogramming after nuclear transfer under the guidance of genetics pioneer Rudolf Jaenisch. Eggan stayed in Jaenisch’s lab for a one-year postdoctoral position in 2002. During that time, he conducted a study with Richard Axel, a Nobel Prize winner at HHMI.